Superworth

Alnylam Pharmaceuticals forward PE ALNY

Share price divided by analysts' consensus earnings for the next twelve months, since 2025.

Today, Nov 3, 2026
18.9×
Peer median
33.8×

Alnylam Pharmaceuticals' forward PE is 18.9× as of Nov 3, 2026.

The median for 10 biotech stocks of a similar size is 33.8×.

Forward PE over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far18.8×18.8×74.0×
202574.1×73.5×163×

Against its peers

Companies in Biotechnology nearest Alnylam Pharmaceuticals' size, closest first, today.

Where Alnylam Pharmaceuticals ranks

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on Alnylam Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.